Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials

Expert Opinion on Investigational Drugs

Volumn 27, Issue 7, 2018, Pages 595-599

  D’Amico, Ferdinando ^a,b   Fiorino, Gionata ^a,b   Furfaro, Federica ^b   Allocca, Mariangela ^a,b   Danese, Silvio ^a,b  

^a HUMANITAS UNIVERSITY   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

future perspectives; IBD; JAK inhibitors; phase I and II clinical trials

Indexed keywords

FILGOTINIB; JANUS KINASE INHIBITOR; PEFICITINIB; PF 06651600; TD 1473; UNCLASSIFIED DRUG; UPADACITINIB; GASTROINTESTINAL AGENT;

DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATORY BOWEL DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CROHN DISEASE; DRUG DESIGN; PATHOPHYSIOLOGY; ULCERATIVE COLITIS;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG DESIGN; GASTROINTESTINAL AGENTS; HUMANS; JANUS KINASE INHIBITORS;

EID: 85050868087     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2018.1492547     Document Type: Review

References (21)

1. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohn’s Colitis. 2010;4:355–366.
2. Ben-Horin S, Chowers Y., Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33:987–995.
3. Flamant M, Rigaill J, Paul S, et al. Advances in the development of Janus kinase inhibitors in inflammatory bowel disease: future prospects. Drugs. 2017;77:1057–1068.
4. Banerjee S, Biehl A, Gadina M, et al. Signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017 Apr;77(5):521–546.
5. Medscape. FDA approves tofacitinib for rheumatoid arthritis. 2012. Access date: 25 May 2018. Available from http://www.medscape.com/viewarticle/774015
6. Medscape. Xeljanz approved for rheumatoid arthritis in European Union. 2017. Access date: 25 May 2018. Available from http://www.medscape.com/viewarticle/877865
7. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
8. Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014 Sep 12 (9):1485–1493.e2. doi:10.1016/j.cgh.2014.01.029 Epub 2014 Jan 27.
9. Coskun M, Salem M, Pedersen J, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013 Oct;76:1–8.
10. Leonard WJ, O’Shea JJ., Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322.
11. Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017 Jul;13(7):693–703.
12. Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G155–62.
13. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009 Mar;228(1):273–287.
14. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med. 2011 Oct 27;365(17):1612–1623.
15. Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin. Pharmacokinet. 54, 859–874.
16. Vermeire S, Schreiber S, Petryka R, et al.; Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. www.thelancet.com, vol 389, 2017 Jan21
17. Selective NP. JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067–1077.
18. Mohamed MEF, Jungerwirth S, Asatryan A, et al.; Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib; Br J Clin Pharmacol (2017) 83 2242–2248
19. Sandborn WJ, Feagan BG, Panes J, et al. Safety and efficacy of ABT-494 (upadacitinib), an oral JAK1 inhibitor, as induction therapy in patients with Crohn’s disease: results from CELEST. 2017;152(5): S1308-S1309. DOI:10.1016/S0016-5085(17)34357-3.
20. Beattie D, Tsuruda P, Shen F, et al. TD-1473, a novel, potent, and orally administered, GI-targeted, pan-Janus kinase (JAK) inhibitor. European Crohn’s and colitis organisation. 2016. Access date: 25 May 2018. Available at: https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2016/item/p069td-1473-a-novel-potent-and-orally-administered-gi-targeted-panjanus-kinase-jak-inhibitor.html
21. Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.